Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Clinical Trials
9
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2005
Active, not recruiting
1
11.1%
Completed
2
22.2%
Recruiting
3
33.3%
Terminated
2
22.2%
Unknown
1
11.1%
No approval data available
- Enlivex Therapeutics announced a $212 million private placement to advance late-stage clinical development of Allocetra, a macrophage reprogramming therapy for osteoarthritis. - The company highlighted the significant unmet medical need, with over 32.5 million Americans and 300 million people worldwide affected by osteoarthritis, and no FDA or EMA-approved therapies capable of arresting structural joint damage. - Former Italian Prime Minister Matteo Renzi was appointed to the board of directors, bringing strategic leadership to the clinical-stage immunotherapy company. - The funding will support both the core clinical development program and a new digital asset treasury strategy centered on RAIN prediction markets.
• Initial data from Enlivex's Phase I/II trial shows Allocetra treatment resulted in 64% average pain reduction in patients with severe knee osteoarthritis who were candidates for knee replacement surgery. • One-third of treated patients experienced complete pain resolution, with pain scores dropping from an average of 9 to 0, demonstrating significant therapeutic potential. • The treatment demonstrated a favorable safety profile in this high-need patient population, marking a potential breakthrough for end-stage osteoarthritis management.
- Enlivex Therapeutics has dosed the first patient in a Phase I clinical trial evaluating Allocetra™ for psoriatic arthritis, with no initial safety concerns. - The trial aims to enroll six patients unresponsive to conventional treatments, assessing safety and changes in pain and disease activity over 12 months. - Allocetra™, an off-the-shelf cell therapy, seeks to reprogram macrophages to their homeostatic state, potentially offering a novel approach for inflammatory conditions. - The psoriatic arthritis treatment market is projected to reach $20.5 billion by 2032, highlighting the need for more effective and safer therapies.
- Enlivex Therapeutics reports positive interim efficacy data from its Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis. - The data showed statistically significant improvements in key endpoints, including pain reduction and improved joint functionality, compared to baseline. - Enlivex has initiated the Phase II stage of the trial, a double-blind, randomized, placebo-controlled study to further assess Allocetra's efficacy and safety. - Allocetra aims to address the unmet need for treatments that can arrest or reverse the progression of osteoarthritis, which affects over 32.5 million Americans.
